NeurologyLive® Friday 5 — November 15, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, October 2024: Approvals, Acceptance, and Hold Removal

The FDA was busy in October 2024, making a number of decisions on potential new therapeutic agents including granting approvals, accepting a resubmitted new drug application, and removing a clinical hold.

2: An IJMSC Spotlight On Caregivers, Individuals With Multiple Sclerosis, and Abuse

A feature on NeurologyLive®, IJMSC Insights offers a look at the data around abuse among patients with MS—which paint a clear and troubling picture.

3: Why Trump and Musk's Alliance Could Launch America's Neurotech Moonshot

Neal K. Shah, CEO at CareYaya Health Technologies, shared his perspective on how the new administration could unleash innovation in neurotech, reduce regulatory barriers with Elon Musk’s involvement, and accelerate innovations that could improve neurological care for those with Alzheimer and dementia.

4: NeuroVoices: David A. Hafler, MD, FANA, on Evolving the MS Diagnostic Criteria to Enhance Precision for Earlier and More Effective Care

In our latest Q&A for NeuroVoices, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed the newly updated multiple sclerosis criteria, highlighting their focus on probabilistic assessment, advanced technology integration, and early intervention to improve patient care.

5: What We Know But Still Have to Learn About Long COVID

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.